Q3 Earnings Forecast for RAPP Issued By HC Wainwright

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – HC Wainwright issued their Q3 2026 earnings per share estimates for Rapport Therapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($1.36) per share for the quarter. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($4.51) EPS, FY2027 earnings at ($6.80) EPS, FY2028 earnings at ($8.40) EPS, FY2029 earnings at ($8.08) EPS and FY2030 earnings at ($6.96) EPS.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07).

A number of other equities research analysts have also recently commented on the stock. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. William Blair assumed coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Friday, July 17th. Finally, BTIG Research restated a “buy” rating and set a $65.00 target price on shares of Rapport Therapeutics in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $57.86.

Rapport Therapeutics Trading Up 3.9%

Shares of NASDAQ:RAPP opened at $48.82 on Monday. The stock has a 50 day moving average of $40.25 and a 200 day moving average of $34.91. The company has a market cap of $2.34 billion, a PE ratio of -16.06 and a beta of 0.97. Rapport Therapeutics has a 12-month low of $13.86 and a 12-month high of $48.94.

Hedge Funds Weigh In On Rapport Therapeutics

Hedge funds have recently modified their holdings of the stock. TRV GP V LLC purchased a new position in Rapport Therapeutics during the second quarter valued at $261,709,477,000. Goldman Sachs Group Inc. increased its holdings in Rapport Therapeutics by 23.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock valued at $91,077,000 after acquiring an additional 579,903 shares during the last quarter. BlackRock Inc. purchased a new stake in Rapport Therapeutics in the 2nd quarter worth $112,500,000. Vanguard Group Inc. lifted its stake in Rapport Therapeutics by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock worth $55,151,000 after purchasing an additional 191,219 shares in the last quarter. Finally, Johnson & Johnson bought a new position in shares of Rapport Therapeutics during the 2nd quarter valued at about $74,360,823,000.

Insider Activity

In related news, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $40.05, for a total transaction of $743,808.60. Following the sale, the insider owned 6,280,525 shares of the company’s stock, valued at approximately $251,535,026.25. This trade represents a 0.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Abraham Ceesay sold 2,210 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $42.11, for a total value of $93,063.10. Following the completion of the transaction, the chief executive officer directly owned 537,607 shares in the company, valued at approximately $22,638,630.77. This represents a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 12.48% of the company’s stock.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.